Medical Cannabis Network Quarterly editor Rosemary Lobley introduces our second edition, which looks at cannabis research, policy and innovation around the world.
Welcome to the second edition of Medical Cannabis Network Quarterly, covering research and policy; national and international regulation of cannabis; and a broad overview of the practicalities surrounding the cannabis industry, from the extraction process to recruiting staff to the particular challenges of cannabis-related finance.
Medical Cannabis Network Quarterly Issue 2
Issue 2 is introduced by former California congressman and longtime cannabis campaigner Dana Rohrabacher, ahead of our North America section, showcasing cannabis innovation in the USA and Canada.
Ancon Development Corporation’s Terry van Gelder introduces us to a new AGT hybrid greenhouse; and Liquid Health Labs highlights a potential solution to the issue of dosing in CBD treatment. urban-gro, Inc demonstrates its innovative new process for cultivation space design; while Cosaint Nectar CEO Philip Tarzai extols the key benefits of CBDA and PURE5, powered by COMERG, reveals novel extraction solutions.
Medical Cannabis Network was fortunate to attend the International Cannabis Business Conference (ICBC) as a media partner, where we met with ICBC founder Alex Rogers; here Rogers tells us about his career as an activist and the future of US policy.
The European section, which opens with the Greek Ministries of Development and Investments and Rural Development and Food, looks at bioavailability with NNE; new developments in the sector with Symtomax; investment and finance with Bryan, Garnier & Co; and medical cannabis treatment with CanPharma. In the UK, meanwhile, ProPharma Group explores the regulation of medical cannabis; while Rize ETF and Currency UK delve further into the complexities of finance within the cannabis industry.
In Latin America, CBD Export Global is working to set an international standard in processing and supplying hemp and cannabis ingredients; and in Israel, Davik aims to provide dynamic solutions for pest control in cannabis cultivation.
Australia’s Cymra Life Sciences showcases its pioneering plant research, followed by a call for evidence-led policy reform by Greg Barns, National Criminal Justice Spokesperson for the Australian Lawyers Alliance.
Elisabetta Faenza, CEO of Leafcann Group, debunks common myths surrounding cannabis; and Emerald Clinics CEO Michael Winlo highlights the benefits of real world evidence bases.
To close this edition, MCN looks at the world of Australian industrial hemp cultivation with craft producers Hemp Fields.